Pfizer said final analysis of its antiviral Covid-19 pill reveals almost 90% efficacy in preventing hospitalizations and deaths among high-risk patients.
In a final study data, Pfizer said its Paxlovid treatment remained 89% effective in preventing hospitalizations in high-risk unvaccinated people when used within three days of the appearance of symptoms.
However, a separate study suggested that the drug failed to meet the primary objective of reducing self-reported symptoms in 673 adults at standard risk of developing Covid-19 complications, Pfizer said. But the drug showed a trend toward reducing hospitalizations in the group by 70%.